Proof-Carrying Data from Multi-folding Schemes

Proof-carrying data (PCD) is a powerful cryptographic primitive that allows mutually distrustful parties to perform distributed computation defined on directed acyclic graphs in an efficiently verifiable manner. Important efficiency parameters include prover\u27s cost at each step and the recursion overhead that measures the additional cost apart from proving the computation. In this paper, we construct a PCD scheme having the smallest prover\u27s cost and recursion overhead in the literature. Specifically, the prover\u27s cost at each step is dominated by only one $O(|C|)$-sized multi-scalar multiplication (MSM), and the recursion overhead is dominated by only one $2r$-sized MSM, where $|C|$ is the computation size and $r$ is the number of incoming edges at certain step. In contrast, the state-of-the-art PCD scheme requires $4r+12$ $O(|C|)$-sized MSMs w.r.t. the prover\u27s cost and six $2r$-sized MSMs, one $6r$-sized MSM w.r.t. the recursion overhead. In addition, our PCD scheme supports more expressive constraint system for computations—customizable constraint system (CCS) that supports high-degree constraints efficiently, in contrast with rank-1 constraint system (R1CS) that supports only quadratic constraints used in existing PCD schemes. Underlying our PCD scheme is a multi-folding scheme that reduces the task of checking multiple instances into the task of checking one. We generalize existing construction to support arbitrary number of instances

Endovascular treatment of middle cerebral artery aneurysms: current status and future prospects

Middle cerebral artery (MCA) aneurysms are complex and widely distributed throughout the course of the MCA. Various types of aneurysms can occur in the MCA. Ruptured as well as unruptured MCA aneurysms may require treatment to avoid bleeding or rebleeding. Currently, clipping is regarded as the first-line choice for the treatment of MCA aneurysms. However, endovascular treatment (EVT) is emerging as an alternative treatment in selected cases. EVT techniques vary. Therefore, it is necessary to review EVT for MCA aneurysms. In this review, the following issues were discussed: MCA anatomy and anomalies, classifications of MCA aneurysms, the natural history of MCA aneurysms, EVT status and principle, deployments of traditional coiling techniques and flow diverters (FDs), and deployments and prospects of intrasaccular flow disruptors and stent-like devices. According to the review and our experience, traditional coiling EVT is still the preferred therapy for most MCA aneurysms. FD deployment can be used in selective MCA aneurysms. Parent artery occlusion (PAO) can be used to treat distal MCA aneurysms. In addition, new devices can be used to treat MCA aneurysms, such as intrasaccular flow disruptors and stent-like devices. In general, EVT is gaining popularity as an alternative treatment option; however, there is still a lack of evidence regarding EVT, and longer-term data are not currently available for most EVT devices

An approach to explore the eddy currents of the new type divertor for EAST device using ANSYS code

An effective method for eddy current calculation has been developed for EAST’s new divertor by using ANSYS. A 3D model of a double null divertor for the EAST device was built to evaluate eddy currents and electromagnetic (EM) forces on these components. The main input to the model is the plasma current and poloidal field coil currents, which are loaded into the model using experimental data measured from the EAST discharges. These currents generate magnetic fields that match those producing an EAST discharge, and the time variation of these fields produces the eddy currents in the divertors, along with from the resulting EM forces. In addition, the first 10 time steps were discussed for the eddy current generation and changing trend. It indicates that a static analysis before a transient mode start can solve the eddy current origination in the initial time steps. With this method, the EM transient response of EAST’s new divertor can be predicted based on ANSYS simulations. Furthermore, the method is also an effective approach to estimate the EM results for the in-vessel components of a fusion reactor during a disruption.National Basic Research Program of China (973 Program) (Grant 2013GB10200

Formation of sclerotia in Sclerotinia ginseng and composition of the sclerotial exudate

Background Sclerotinia ginseng is a major devastating soil-borne pathogen of ginseng that can cause irreparable damage and large economic losses. This pathogen produces sclerotia, which are among the most persistent resting structures produced by filamentous fungi. The production of an exudate is a common feature of sclerotial development. Methods S. ginseng was cultured on 10 different media and the following parameters were measured: mycelial growth rate (mm/day), initial formation time of exudate droplets, total quantity of exudate, number of sclerotia per dish, and sclerotial fresh/dry weight. The composition of the sclerotial exudate was analyzed using four methods (high performance liquid chromatography, gas chromatography-mass spectrometry, flame atomic absorption spectrometry, and Nessler’s reagent spectrophotometry). Results We found that PDA was the optimal medium for exudate production, while SDA medium resulted in the highest mycelial growth rate. The earliest emergence of exudate droplets from sclerotia was on OA-YE and V8 media. The largest amount of sclerotia and the smallest sclerotia were produced on V8 medium. The maximum and minimum dry/fresh weight were obtained on MEA medium and V8 medium, respectively. The exudate contained organic acids (oxalic acid, gallic acid, ferulic acid, vanillic acid, caffeic acid, and tannic acid), carbohydrates (inositol, glucose, and trehalose), various ions (potassium, sodium, and magnesium), and ammonia. Discussion The functions of the identified compounds are discussed within the context of pathogenicity, sclerotial development, and antimicrobial activity. Our findings provide information about the production of sclerotia and the composition of sclerotial exudate that may be useful to develop strategies to control this disease

The Synthesis and Initial Evaluation of MerTK Targeted PET Agents

MerTK (Mer tyrosine kinase), a receptor tyrosine kinase, is ectopically or aberrantly expressed in numerous human hematologic and solid malignancies. Although a variety of MerTK targeting therapies are being developed to enhance outcomes for patients with various cancers, the sensitivity of tumors to MerTK suppression may not be uniform due to the heterogeneity of solid tumors and different tumor stages. In this report, we develop a series of radiolabeled agents as potential MerTK PET (positron emission tomography) agents. In our initial in vivo evaluation, [18F]-MerTK-6 showed prominent uptake rate (4.79 ± 0.24%ID/g) in B16F10 tumor-bearing mice. The tumor to muscle ratio reached 1.86 and 3.09 at 0.5 and 2 h post-injection, respectively. In summary, [18F]-MerTK-6 is a promising PET agent for MerTK imaging and is worth further evaluation in future studies

PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using 64 Cu-Labeled Monoclonal Antibody 61B

Delta-like ligand 4 (Dll4) expressed in tumor cells plays a key role to promote tumor growth of numerous cancer types. Based on a novel anti-human Dll4 monoclonal antibody (61B), we developed a (64)Cu-labeled probe for positron emission tomography (PET) imaging of tumor Dll4 expression. In this study, 61B was conjugated with the (64)Cu-chelator DOTA through lysine on the antibody. Human IgG (hIgG)-DOTA, which did not bind to Dll4, was also prepared as a control. The Dll4 binding activity of the probes was evaluated through the bead-based binding assay with Dll4-alkaline phosphatase. The resulting PET probes were evaluated in U87MG glioblastoma and HT29 colorectal cancer xenografts in athymic nude mice. Our results demonstrated that the 61B-DOTA retained (77.2 ± 3.7) % Dll4 binding activity of the unmodified 61B, which is significantly higher than that of hIgG-DOTA (0.06 ± 0.03) %. Confocal microscopy analysis confirmed that 61B-Cy5.5, but not IgG-Cy5.5, predominantly located within the U87MG and HT29 cells cytoplasm. U87MG cells showed higher 61B-Cy5.5 binding as compared to HT29 cells. In U87MG xenografts, 61B-DOTA-(64)Cu demonstrated remarkable tumor accumulation (10.5 ± 1.7 and 10.2 ± 1.2 %ID/g at 24 and 48 hour post injection, respectively). In HT29 xenografts, tumor accumulation of 61B-DOTA-(64)Cu was significantly lower than that of U87MG (7.3 ± 1.3 and 6.6 ± 1.3 %ID/g at 24 and 48 hour post injection, respectively). The tumor accumulation of 61B-DOTA-(64)Cu was significantly higher than that of hIgG-DOTA-(64)Cu in both xenografts models. Immunofluorescence staining of the tumor tissues further confirmed that tumor accumulation of 61B-Cy5.5 was correlated well with in vivo PET imaging data using 61B-DOTA-(64)Cu. In conclusion, 61B-DOTA-(64)Cu PET probe was successfully synthesized and demonstrated prominent tumor uptake by targeting Dll4. 61B-DOTA-(64)Cu has great potential to be used for noninvasive Dll4 imaging, which could be valuable for tumor detection, Dll4 expression level evaluation, and Dll4-based treatment monitoring

Nano-channel-based physical and chemical synergic regulation for dendrite-free lithium plating

Uncontrollable dendrite growth resulting from the non-uniform lithium ion (Li+) flux and volume expansion in lithium metal (Li) negative electrode leads to rapid performance degradation and serious safety problems of lithium metal batteries. Although N-containing functional groups in carbon materials are reported to be effective to homogenize the Li+ flux, the effective interaction distance between lithium ions and N-containing groups should be relatively small (down to nanometer scale) according to the Debye length law. Thus, it is necessary to carefully design the microstructure of N-containing carbon materials to make the most of their roles in regulating the Li+ flux. In this work, porous carbon nitride microspheres (PCNMs) with abundant nanopores have been synthesized and utilized to fabricate a uniform lithiophilic coating layer having hybrid pores of both the nano- and micrometer scales on the Cu/Li foil. Physically, the three-dimensional (3D) porous framework is favorable for absorbing volume changes and guiding Li growth. Chemically, this coating layer can render a suitable interaction distance to effectively homogenize the Li+ flux and contribute to establishing a robust and stable solid electrolyte interphase (SEI) layer with Li-F, Li-N, and Li-O-rich contents based on the Debye length law. Such a physical-chemical synergic regulation strategy using PCNMs can lead to dendrite-free Li plating, resulting in a low nucleation overpotential and stable Li plating/stripping cycling performance in both the Li‖Cu and the Li‖Li symmetric cells. Meanwhile, a full cell using the PCNM coated Li foil negative electrode and a LiFePO4 positive electrode has delivered a high capacity retention of ∼ 80% after more than 200 cycles at 1 C and achieved a remarkable rate capability. The pouch cell fabricated by pairing the PCNM coated Li foil negative electrode with a NCM 811 positive electrode has retained ∼ 73% of the initial capacity after 150 cycles at 0.2 C